Copyright Reports & Markets. All rights reserved.

Global Macular Degeneration Drug Pipeline Market Status and Forecast 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Macular Degeneration Drug Pipeline Market Status and Forecast (2016-2027)
      • 1.3.2 Global Macular Degeneration Drug Pipeline Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Macular Degeneration Drug Pipeline Supply by Company

    • 2.1 Global Macular Degeneration Drug Pipeline Sales Value by Company
    • 2.2 Macular Degeneration Drug Pipeline Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Macular Degeneration Drug Pipeline Market Status by Type

    • 3.1 Macular Degeneration Drug Pipeline Type Introduction
      • 3.1.1 Gene therapy
      • 3.1.2 Small molecules
      • 3.1.3 Stem cell therapy
      • 3.1.4 Gene therapies
    • 3.2 Global Macular Degeneration Drug Pipeline Market by Type
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Macular Degeneration Drug Pipeline Market Status by Application

    • 4.1 Macular Degeneration Drug Pipeline Segment by Application
      • 4.1.1 Hospital
      • 4.1.2 Research Institute
      • 4.1.3 Commercial
      • 4.1.4 Other
    • 4.2 Global Macular Degeneration Drug Pipeline Market by Application
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Macular Degeneration Drug Pipeline Market Status by Region

    • 5.1 Global Macular Degeneration Drug Pipeline Market by Region
    • 5.2 North America Macular Degeneration Drug Pipeline Market Status
    • 5.3 Europe Macular Degeneration Drug Pipeline Market Status
    • 5.4 Asia Pacific Macular Degeneration Drug Pipeline Market Status
    • 5.5 Central & South America Macular Degeneration Drug Pipeline Market Status
    • 5.6 Middle East & Africa Macular Degeneration Drug Pipeline Market Status

    6 North America Macular Degeneration Drug Pipeline Market Status

    • 6.1 North America Macular Degeneration Drug Pipeline Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Macular Degeneration Drug Pipeline Market Status

    • 7.1 Europe Macular Degeneration Drug Pipeline Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Macular Degeneration Drug Pipeline Market Status

    • 8.1 Asia Pacific Macular Degeneration Drug Pipeline Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Macular Degeneration Drug Pipeline Market Status

    • 9.1 Central & South America Macular Degeneration Drug Pipeline Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Macular Degeneration Drug Pipeline Market Status

    • 10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Macular Degeneration Drug Pipeline Market Forecast by Type and by Application

    • 12.1 Global Macular Degeneration Drug Pipeline Sales Value Forecast (2022-2027)
    • 12.2 Global Macular Degeneration Drug Pipeline Forecast by Type
    • 12.3 Global Macular Degeneration Drug Pipeline Forecast by Application

    13 Global Macular Degeneration Drug Pipeline Market Forecast by Region/Country

    • 13.1 Global Macular Degeneration Drug Pipeline Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Sinocelltech
      • 14.1.1 Company Information
      • 14.1.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.1.3 Sinocelltech Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Shanghai Henlius Biotech
      • 14.2.1 Company Information
      • 14.2.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.2.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Roche
      • 14.3.1 Company Information
      • 14.3.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.3.3 Roche Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Ribomic
      • 14.4.1 Company Information
      • 14.4.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.4.3 Ribomic Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 RemeGen
      • 14.5.1 Company Information
      • 14.5.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.5.3 RemeGen Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Outlook Therapeutics
      • 14.6.1 Company Information
      • 14.6.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.6.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Lineage Cell Therapeutics
      • 14.7.1 Company Information
      • 14.7.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.7.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Kyowa Kirin
      • 14.8.1 Company Information
      • 14.8.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.8.3 Kyowa Kirin Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Kodiak Sciences
      • 14.9.1 Company Information
      • 14.9.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.9.3 Kodiak Sciences Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 IVERIC Bio
      • 14.10.1 Company Information
      • 14.10.2 Macular Degeneration Drug Pipeline Product Introduction
      • 14.10.3 IVERIC Bio Macular Degeneration Drug Pipeline Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Grifols, S.A.
    • 14.12 Graybug Vision
    • 14.13 EyePoint Pharmaceutical
    • 14.14 CHABiotech
    • 14.15 Bio-Thera Solutions
    • 14.16 Bioeq AG
    • 14.17 AsclepiX Therapeutics
    • 14.18 Amgen
    • 14.19 Alteogen
    • 14.20 Adverum Biotechnologies

    15 Conclusion

      16 Methodology

      This report provides a comprehensive analysis of current global Macular Degeneration Drug Pipeline market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Macular Degeneration Drug Pipeline industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

      According to this survey, the global Macular Degeneration Drug Pipeline market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

      Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Macular Degeneration Drug Pipeline Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Macular Degeneration Drug Pipeline market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

      The Global Macular Degeneration Drug Pipeline Market has been exhibited in detail in the following chapters
      Chapter 1 displays the basic product introduction and market overview.
      Chapter 2 provides the competition landscape of global Macular Degeneration Drug Pipeline industry.
      Chapter 3 provides the market analysis by type and by region
      Chapter 4 provides the market analysis by application and by region
      Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
      Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
      Chapter 12 provides the market forecast by type and by application
      Chapter 13 provides the market forecast by region
      Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
      Chapter 15 conclusions

      Segmented by Type
      Gene therapy
      Small molecules
      Stem cell therapy
      Gene therapies

      Segmented by Application
      Hospital
      Research Institute
      Commercial
      Other

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Sinocelltech
      Shanghai Henlius Biotech
      Roche
      Ribomic
      RemeGen
      Outlook Therapeutics
      Lineage Cell Therapeutics
      Kyowa Kirin
      Kodiak Sciences
      IVERIC Bio
      Grifols, S.A.
      Graybug Vision
      EyePoint Pharmaceutical
      CHABiotech
      Bio-Thera Solutions
      Bioeq AG
      AsclepiX Therapeutics
      Amgen
      Alteogen
      Adverum Biotechnologies
      Buy now